Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
May 21, 2026
Oracle (ORCL) Attracts Fresh Analyst Upgrades as Cloud and AI Initiatives Gain Traction

Oracle (ORCL) Attracts Fresh Analyst Upgrades as Cloud and AI Initiatives Gain Traction

Key Takeaways

  • Oracle Corporation continues to strengthen its position in cloud infrastructure and artificial intelligence (AI) services amid sustained demand.
  • Multiple Wall Street analysts raised price targets in mid-May 2026, reflecting confidence in long-term growth drivers.
  • Recent board additions and software AI enhancements support the company’s strategic expansion plans.
  • Investor sentiment remains tied to Oracle’s ability to execute on large-scale AI infrastructure commitments.
  • Broader technology sector trends and macroeconomic conditions continue to influence trading patterns.

Current Market Snapshot

In recent weeks, ORCL shares have experienced notable volatility within a broader technology sector rebound. The stock has traded in a range influenced by mixed daily moves, with investors closely monitoring developments in the company’s cloud and AI initiatives. Overall market sentiment has reflected cautious optimism, as participants weigh the firm’s growth prospects against ongoing capital expenditure requirements. Trading volumes have remained elevated during this period, indicating active interest from both institutional and retail investors. From what I see, the general state of the shares suggests a market digesting recent analyst commentary and industry tailwinds without a clear directional consensus in the latest market cycle.

Recent Developments Driving ORCL Price Action

During the past 30 days, several developments shaped investor views on Oracle Corporation. On May 13, 2026, Wedbush Securities raised its price target to $275 from $225 while maintaining a Buy rating, citing accelerating demand for the company’s cloud infrastructure offerings. The move contributed to positive sentiment, as it highlighted Oracle’s expanding role in supporting hyperscale AI workloads. Similarly, on May 12, Oppenheimer lifted its target to $235 from $210, also with a Buy recommendation, pointing to robust remaining performance obligations and expected revenue growth in fiscal 2026.

Additional analyst actions included new Buy initiations from multiple firms, reinforcing a favorable consensus. On May 12, Oracle appointed healthcare executive Tomislav Mihaljevic to its board of directors, a step viewed as strengthening governance and strategic oversight in key verticals. The appointment coincided with continued emphasis on AI-enhanced software solutions, including updates to utilities and NetSuite platforms that integrate machine learning capabilities. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Earlier in the period, market participants reacted to clarifications from OpenAI’s finance chief regarding demand strength, alleviating concerns tied to a major infrastructure partnership. These updates helped stabilize sentiment after brief fluctuations linked to broader AI spending narratives. Macroeconomic factors, including interest rate expectations and technology sector rotation, also played a role in price behavior, though company-specific catalysts dominated attention. Overall, the combination of upgraded targets, board refreshment, and reaffirmed AI momentum supported a constructive tone in trading sessions throughout the period.

Exploring AI Trading Bots for Portfolio Ideas

In my own research process, I sometimes turn to Tickeron’s AI Trading Bots to test different automated strategies against names like ORCL. These bots cover a range of styles and timeframes, and I find it helpful to see how various risk parameters perform in the current environment before forming a fuller view on positioning.

2026 Outlook and Key Factors to Monitor

Looking ahead to the remainder of 2026, Oracle Corporation’s trajectory will likely hinge on execution of its cloud infrastructure expansion and AI service adoption. Key themes include sustained capital expenditures to meet growing demand for high-performance computing resources, alongside efforts to broaden enterprise software offerings with embedded artificial intelligence features. Investors may track progress on large-scale contracts, particularly those involving cloud infrastructure revenue targets previously outlined by management.

Competitive positioning within the AI ecosystem, regulatory developments affecting data centers, and shifts in customer spending patterns represent important variables. Cost management and supply chain considerations for hardware components will also warrant attention, as will any updates to fiscal guidance. Long-term growth drivers such as digital transformation initiatives across industries provide a supportive backdrop, yet execution risks and macroeconomic uncertainties remain relevant considerations for market participants. I’m watching this closely as the year progresses.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: ORCL

ORCL's RSI Indicator climbs out of oversold territory

The RSI Oscillator for ORCL moved out of oversold territory on July 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on ORCL as a result. In of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ORCL just turned positive on July 22, 2026. Looking at past instances where ORCL's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ORCL advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ORCL broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ORCL entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.173) is normal, around the industry mean (25.264). P/E Ratio (24.998) is within average values for comparable stocks, (78.872). Projected Growth (PEG Ratio) (0.824) is also within normal values, averaging (1.951). Dividend Yield (0.014) settles around the average of (0.021) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (147.729).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ORCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), MongoDB (NASDAQ:MDB), Twilio (NYSE:TWLO), Zscaler (NASDAQ:ZS), Okta (NASDAQ:OKTA).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 34.99B. The market cap for tickers in the group ranges from 48.8K to 3.66T. MSFT holds the highest valuation in this group at 3.66T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 9%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 22%. BLZE experienced the highest price growth at 64%, while CSAI experienced the biggest fall at -98%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was 39%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 72
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 91
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
ORCL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of a diversified line of business software products

Industry ComputerCommunications

Profile
Details
Industry
Packaged Software
Address
2300 Oracle Way
Phone
+1 737 867-1000
Employees
164000
Web
https://www.oracle.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.